178908-09-3
| 中文名称 | 178908-09-3 |
|---|---|
| 中文同义词 | 化合物 T13248;化合物UK-240455 |
| 英文名称 | UK-240455 |
| 英文同义词 | UK-240455;Methanesulfonamide, N-(6,7-dichloro-1,2,3,4-tetrahydro-2,3-dioxo-5-quinoxalinyl)-N-(2-hydroxyethyl)-;UK 240455,UK240455 |
| CAS号 | 178908-09-3 |
| 分子式 | C11H11Cl2N3O5S |
| 分子量 | 368.19 |
| EINECS号 | |
| 相关类别 | |
| Mol文件 | 178908-09-3.mol |
| 结构式 |  |
178908-09-3 性质
| 密度 | 1.686±0.06 g/cm3(Predicted) |
|---|---|
| 储存条件 | Store at -20°C |
| 溶解度 | 溶于二甲基亚砜 |
| 酸度系数(pKa) | 7.96±0.20(Predicted) |
UK-240455 是一个有效且有选择性的 N-甲基 D-天冬氨酸 (NMDA) 甘氨酸位点上的拮抗剂。
NMDA
UK-240455 is a potent and selective N-methyl D-aspartate (NMDA) glycine site antagonist. Following i.v. administration of UK-240455 to male rats, UK-240455 has a clearance of 12 mL/min/kg and a volume of distribution of 0.4 L/kg. The plasma concentration of UK-240455 decreases with an apparent half-life of 0.4 h. Analysis of urine (0 to 24 h) for unchanged UK-240455 indicates that 57% of the dose administered is excreted unchanged in the urine. The urinary clearance of UK-240455 in the rat is therefore 7 mL/min/kg. Following oral administration of UK-240455 to male rats, the apparent elimination half-life of UK-240455 from plasma following oral administration is 1.6 h.